Sugi Predict

Sugi Predict / Compounds / Serine

Serine

Serine

SCHEMBL312921

N[C@@H](CO)C(=O)O.Nc1ncco1

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ARG1 P05089 1/20 0.37
▸ SLC1A1 P43005 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ KMO O15229 2/20 0.33
▸ ALPI P09923 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ PTGS1 P23219 1/20 0.33
▸ XIAP P98170 1/20 0.33
▸ SLC7A5 Q01650 1/20 0.33
▸ KIF11 P52732 1/20 0.33
▸ GRM8 O00222 1/20 0.33
▸ GRM4 Q14833 1/20 0.33
▸ GRIN3B O60391 1/20 0.32
▸ GRIN1 Q05586 1/20 0.32
▸ GRIN2C Q14957 1/20 0.32
▸ GRIA1 P42261 1/20 0.32
▸ GRIA2 P42262 1/20 0.32
▸ GRIA3 P42263 1/20 0.32
▸ GRIA4 P48058 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163433 0.73 — —
SCHEMBL15390305 0.72 HSD17B10 (0.44) HSD17B10CYP1A2ALPIPKMPTGS1
SCHEMBL13957542 0.72 HSD17B10 (0.44) HSD17B10CYP1A2ALPIPKMPTGS1
Serine SCHEMBL28012353 0.72 SLC1A1 (0.43) SLC1A1HSD17B10CYP1A2ALPIPKM
Serine SCHEMBL28012352 0.72 SLC1A1 (0.43) SLC1A1HSD17B10CYP1A2ALPIPKM
Trifluoroacetic Acid SCHEMBL25401305 0.72 L3MBTL1 (0.38) HSD17B10
Serine SCHEMBL11873518 0.71 SLC1A1 (0.54) SLC1A1CYP1A2ALPIPKMPTGS1
Serine SCHEMBL19463572 0.71 — —
Serine SCHEMBL3449824 0.71 SLC1A1 (0.54) SLC1A1CYP1A2ALPIPKMPTGS1
Serine SCHEMBL19463404 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8729060-B2 Macrocyclic polyoxazole compounds and use thereof RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2014-05-20 — — US disclosed
US-8518928-B2 Therapeutic compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2013-08-27 — — US disclosed
US-20120071527-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) 2012-03-22 — — US disclosed
US-8093235-B2 Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2012-01-10 — — US disclosed
US-20110230531-A1 THERAPEUTIC COMPOUNDS NIH - DEITR 2011-09-22 — — US disclosed
EP-2183256-A1 THERAPEUTIC COMPOUNDS Rutgers, The State University of New Jersey (US) 2010-05-12 — — EP disclosed
EP-2079704-A2 THERAPEUTIC COMPOUNDS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2009-07-22 — — EP disclosed
US-20090156627-A1 THERAPEUTIC COMPOUNDS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2009-06-18 — — US disclosed
WO-2009018549-A1 THERAPEUTIC COMPOUNDS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2009-02-05 — — WO disclosed
WO-2007127173-A2 THERAPEUTIC COMPOUNDS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2007-11-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156627-A1 THERAPEUTIC COMPOUNDS TOP2B, DDB1, RECQL ARG1 1880/4885SLC1A1 4126/4885HSD17B10 3715/4885
US-20120071527-A1 THERAPEUTIC COMPOUNDS TOP2B, DDB1, TOP1 ARG1 2175/4885SLC1A1 4155/4885HSD17B10 3663/4885
US-20110230531-A1 THERAPEUTIC COMPOUNDS MCL1, MKI67, NCL ARG1 432/4885SLC1A1 2175/4885HSD17B10 2281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.